Drug Profile
Gedatolisib - Celcuity
Alternative Names: PF-05212384; PF-5212384; PKI-587Latest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Celcuity; Pfizer
- Class Antineoplastics; Morpholines; Piperidines; Small molecules; Triazines; Urea compounds
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Breast cancer
- Phase I/II Prostate cancer
- Discontinued Acute myeloid leukaemia; Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 22 Feb 2024 Phase-I/II clinical trials in Prostate cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line Therapy or greater, Hormone refractory) in France (IV) (NCT06190899)
- 06 Dec 2023 Pharmacodynamics data from a preclinical trial in Breast cancer released by Celcuity
- 05 Dec 2023 Efficacy and adverse events data from a phase I/II trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)